Document is current
Any future updates will be listed below
-
Authors
Chaudhary, Lubna N. https://orcid.org/0000-0003-0616-6135
Jorns, Julie M.
Sun, Yunguang
Cheng, Yee Chung
Kamaraju, Sailaja
Burfeind, John
Gonyo, Mary Beth
Kong, Amanda L.
Patten, Caitlin
Yen, Tina
Cortina, Chandler S.
Carson, Ebony
Johnson, Nedra
Bergom, Carmen
Tsaih, Shirng-Wern
Banerjee, Anjishnu
Wang, Yu
Chervoneva, Inna
Weil, Elizabeth
Chitambar, Christopher R.
Rui, Hallgeir
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03219476 at ClinicalTrials.govDocuments that mention this clinical trial
Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy
https://doi.org/10.1007/s10549-023-07038-3
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (KL2TR001438, R03 CA259594, R01 CA267549)
- License Information
-
More Information
Article History
Received: 4 April 2023
Accepted: 5 July 2023
First Online: 17 July 2023
Declarations
:
: Lubna N, Chaudhary has received consultant and advisory boards honoraria Puma Biotechnology, Seattle Genetics, Gilead Oncology, AstraZeneca, and Novartis Advisory as well as grant from Regeneron Pharmaceuticals outside the submitted work. Other authors have no financial interests to disclose.
